Quick Order

Human VCAM-1 / CD106 Protein (His Tag)

DatasheetReviewsProtocols
Reactivity: Human  
Application: 
  • Slide 1
  • Slide 1
  • Slide 1
100507-T38-50
100507-T38-200
100507-T38-100
50 µg 
200 µg 
100 µg 
Add to Cart
Reactivity: Human  
Application: ELISA  
    10113-RP01-400
    10113-RP01-200
    10113-RP01-100
    400 µg 
    200 µg 
    100 µg 
    Add to Cart
    Reactivity: Human  
    Application: WB  
    • Slide 1
    10113-T32-50
    10113-T32-200
    10113-T32-100
    50 µg 
    200 µg 
    100 µg 
    Add to Cart
    Reactivity: Mouse  
    Application: 
      50163-T16-50
      50163-T16-200
      50163-T16-100
      50 µg 
      200 µg 
      100 µg 
      Add to Cart
      Reactivity: Mouse  
      Application: ELISA  
        50163-R130-50
        50163-R130-100
        50 µg 
        100 µg 
        Add to Cart
        Reactivity: Mouse  
        Application: ELISA  
          50163-R119-50
          50163-R119-100
          50 µg 
          100 µg 
          Add to Cart
          Reactivity: Mouse  
          Application: ELISA  
            50163-RP02-50
            50163-RP02-200
            50163-RP02-100
            50 µg 
            200 µg 
            100 µg 
            Add to Cart
            Reactivity: Mouse  
            Application: ELISA  
              50163-RP01-400
              50163-RP01-200
              50163-RP01-100
              400 µg 
              200 µg 
              100 µg 
              Add to Cart

              VCAM1/VCAM-1/CD106 Recombinant ProteinRelated Products

              Related Products

              Featured Reagent Products

              VCAM1/VCAM-1/CD106 protein Background

              Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.

              Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

              Human VCAM1/VCAM-1/CD106 protein References
            • Cook-Mills JM. (2002) VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. Mol Immunol. 39(9): 499-508.
            • Preiss DJ, et al. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract. 61(4): 697-701.
            • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"